Brain superoxide anion generation in asphyxiated piglets and the effect of indomethacin at therapeutic dose.
We have previously shown that generation of superoxide anion occurs in cerebral cortex during asphyxia/reventilation in newborn pigs and that a high dose of indomethacin (5 mg/kg i.v.) abolishes superoxide anion production. The purposes of this study were 1) to determine whether the generation of superoxide anion occurs primarily during asphyxia or whether reventilation must take place, 2) to investigate the effects of indomethacin pretreatment at a therapeutic dose of 0.2 mg/kg i.v. on superoxide anion generation, and 3) to investigate the effects of oxypurinol, an oxygen free radical scavenger, on superoxide anion production during asphyxia/reventilation. Superoxide anion production on cerebral cortex was determined by superoxide dismutase-inhibitable nitroblue tetrazolium (NBT) reduction using closed cranial windows. Superoxide anion generation during asphyxia without reventilation was 4 +/- 2 pmol NBT/mm2 per 20 min, which was significantly lower than during asphyxia/reventilation (16 +/- 4 pmol NBT/mm2 per 20 min) but comparable to the control group (3 +/- 1 pmol NBT/mm2 per 20 min). Indomethacin given at therapeutic dosage before asphyxia/reventilation decreased superoxide anion production to 3 +/- 1 pmol NBT/mm2 per 20 min, values not significantly different from the control group and from piglets pretreated with oxypurinol at a dose of 50 mg/kg i.v. (4 +/- 2 pmol NBT/mm2 per 20 min). We conclude that in newborn pigs 1) superoxide anions are generated largely during reventilation rather than during asphyxia; 2) the therapeutic dose of indomethacin (0.2 mg/kg) is effective in inhibiting the superoxide anion generation during asphyxia/reventilation; and 3) oxypurinol reduces the superoxide anion accumulation on cerebral cortex during asphyxia/reventilation.
Pourcyrous
M
M
Department of Pediatrics, University of Tennessee, Memphis 38163.
Leffler
C W
CW
Bada
H S
HS
Korones
S B
SB
Busija
D W
DW
D000818:Animals; D000831:Animals, Newborn; D001238:Asphyxia Neonatorum / Q000188:drug therapy / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D004195:Disease Models, Animal; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology* / Q000627:therapeutic use; D007231:Infant, Newborn; D010100:Oxygen / Q000008:administration & dosage / Q000378:metabolism*; D010117:Oxypurinol / Q000494:pharmacology / Q000627:therapeutic use; D017382:Reactive Oxygen Species; D012121:Respiration, Artificial / Q000009:adverse effects*; D013481:Superoxides / Q000378:metabolism*; D013552:Swine
D017382:Reactive Oxygen Species; D013481:Superoxides; D010117:Oxypurinol; D010100:Oxygen; D007213:Indomethacin